Items Tagged ‘EGFR’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


November 16th, 2015

New Lab Test Enables Precision Treatment for Lung Cancer

By

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States. Opdivo, a PD 1 […]

View full entry

Tags: alk, EGFR, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell, opdivo, PD-L1 levels, xalkori


December 4th, 2014

Esophageal Cancer Survival Improved Using Targeted Therapy Developed in Lung Cancer

By

Targeted therapy commonly used in lung cancer improves survival of esophageal cancer patients according to clinical trial results recently presented at the National Cancer Research Institute (NCRI) Cancer Conference in the UK. The esophagus is a muscular tube that food and liquids pass through on their on their way to the stomach. Each year in the […]

View full entry

Tags: EGFR, Esophageal Cancer, iressa, News, Stage IV/Recurrent Esophageal Cancer


August 5th, 2014

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors

By

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped responding to the EGFR inhibitors Tarceva® (erlotinib) and Iressa® (gefitinib). This novel combination appeared to benefit patients regardless of whether their […]

View full entry

Tags: EGFR, erbitux, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell